Venetoclax or Pirtobrutinib in Relapsed/Refractory Waldenström Macroglobulinemia: Clinical and Molecular Predictors and Sequencing Implications - PubMed
4 days ago
- #Pirtobrutinib
- #Waldenström macroglobulinemia
- #Venetoclax
- Venetoclax and pirtobrutinib are chemotherapy-free options for relapsed/refractory Waldenström macroglobulinemia (WM).
- TP53 alterations in the venetoclax cohort were associated with shorter progression-free survival (PFS).
- CXCR4 mutations in the pirtobrutinib cohort predicted lower major response rate (MRR) and shorter PFS.
- IgM rebound occurred in 62% of patients transitioning from a cBTKi to venetoclax without overlap, but not with pirtobrutinib.
- Venetoclax and pirtobrutinib showed comparable efficacy in MRR and PFS in a matched cohort analysis.
- The study supports considering pirtobrutinib sequencing when transitioning from a cBTKi and exploring combination strategies.